InflaRx

Company snapshot

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammator

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for InflaRx. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for InflaRx.

1. Jun 8, 2026 Clinical update

   IFX-1-P3.4 — Phase 3

2. Jun 8, 2026 Clinical update

   INF904-P1.3 — Phase 1

3. Jun 8, 2026 Clinical update

   INF904-P1.2 — Phase 1

4. Jun 5, 2026 Clinical update

   INF904 — Phase 2

View all clinical trial activity →

• What is InflaRx?

  InflaRx is a pharma organization headquartered in Jena, DE. Primary therapeutic focus areas include Not applicable, healthy volunteers, ulcerative pyoderma gangrenosum. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from publi

• Is InflaRx publicly traded?

  InflaRx appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does InflaRx develop or market?

  We link 20 drug profile(s) where InflaRx is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/inflarx-gmbh#company-drugs.

• What are the latest developments for InflaRx?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does InflaRx focus on?

  InflaRx focuses on Not applicable, healthy volunteers, ulcerative pyoderma gangrenosum based on our analysis of their pipeline programs and drug development activities.